New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease

Over the past few decades, atherogenic dyslipidaemia has become one of the most common phenotypic presentations of lipid abnormalities, being strongly and unequivocally associated with an increased risk of cardiovascular (CV) disease. Despite the excellent results achieved from statin and non-statin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alberto J Lorenzatti, Peter P Toth
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/a811fc3ce3924d8caabd2cbb418db7ca
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a811fc3ce3924d8caabd2cbb418db7ca
record_format	dspace
spelling	oai:doaj.org-article:a811fc3ce3924d8caabd2cbb418db7ca2021-12-04T16:02:28ZNew Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease10.15420/ecr.2019.061758-37641758-3756https://doaj.org/article/a811fc3ce3924d8caabd2cbb418db7ca2020-02-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2019.06https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Over the past few decades, atherogenic dyslipidaemia has become one of the most common phenotypic presentations of lipid abnormalities, being strongly and unequivocally associated with an increased risk of cardiovascular (CV) disease. Despite the excellent results achieved from statin and non-statin management of LDL cholesterol and CV events prevention, there still remains a significant residual risk, associated with the prevalence of non-LDL cholesterol lipid patterns characterised by elevated triglyceride levels, low HDL cholesterol, a preponderance of small and dense LDL particles, accumulation of remnant lipoproteins and postprandial hyperlipidaemia. These qualitative and quantitative lipid modifications are largely associated with insulin resistance, type 2 diabetes and obesity, the prevalence of which has grown to epidemic proportions throughout the world. In this review, we analyse the pathophysiology of this particular dyslipidaemia, its relationship with the development of atherosclerotic CV disease and, finally, briefly describe the therapeutic approaches, including changes in lifestyle and current pharmacological interventions to manage these lipid alterations aimed at preventing CV events.Alberto J LorenzattiPeter P TothRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 15, Iss , Pp - (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Alberto J Lorenzatti Peter P Toth New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
description	Over the past few decades, atherogenic dyslipidaemia has become one of the most common phenotypic presentations of lipid abnormalities, being strongly and unequivocally associated with an increased risk of cardiovascular (CV) disease. Despite the excellent results achieved from statin and non-statin management of LDL cholesterol and CV events prevention, there still remains a significant residual risk, associated with the prevalence of non-LDL cholesterol lipid patterns characterised by elevated triglyceride levels, low HDL cholesterol, a preponderance of small and dense LDL particles, accumulation of remnant lipoproteins and postprandial hyperlipidaemia. These qualitative and quantitative lipid modifications are largely associated with insulin resistance, type 2 diabetes and obesity, the prevalence of which has grown to epidemic proportions throughout the world. In this review, we analyse the pathophysiology of this particular dyslipidaemia, its relationship with the development of atherosclerotic CV disease and, finally, briefly describe the therapeutic approaches, including changes in lifestyle and current pharmacological interventions to manage these lipid alterations aimed at preventing CV events.
format	article
author	Alberto J Lorenzatti Peter P Toth
author_facet	Alberto J Lorenzatti Peter P Toth
author_sort	Alberto J Lorenzatti
title	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
title_short	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
title_full	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
title_fullStr	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
title_full_unstemmed	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
title_sort	new perspectives on atherogenic dyslipidaemia and cardiovascular disease
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/a811fc3ce3924d8caabd2cbb418db7ca
work_keys_str_mv	AT albertojlorenzatti newperspectivesonatherogenicdyslipidaemiaandcardiovasculardisease AT peterptoth newperspectivesonatherogenicdyslipidaemiaandcardiovasculardisease
_version_	1718372753146380288

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease

Ejemplares similares